| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30040174 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040175 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040176 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040177 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040178 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040179 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040180 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040181 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040182 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
| TVIS30040183 | HIV | ENSG00000140992.20 | protein_coding | PDPK1 | No | No | 5170 | O15530 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PDPK1 |
|---|---|
| DrugBank ID | DB00482 |
| Drug Name | Celecoxib |
| Target ID | BE0001193 |
| UniProt ID | O15530 |
| Regulation Type | inhibitor |
| PubMed IDs | 14973075; 15205346; 16060857; 16455452; 16887935 |
| Citations | Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004 Feb 15;64(4):1444-51.@@Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. doi: 10.1158/0008-5472.CAN-03-4063.@@Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005 Oct 15;391(Pt 2):441-8.@@Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg. 2006 Feb;10(2):207-14.@@Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpyrazoles |
| SMILES | CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F |
| Pathways | Celecoxib Action Pathway; Celecoxib Metabolism Pathway |
| PharmGKB | PA448871 |
| ChEMBL | CHEMBL118 |
